Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Chemistry

Abstract 1972: Active targeting, fluorescence imaging, and NIR photothermal therapy of malignant tumors

Hadiyah-Nicole Green, William E. Grizzle, Eben L. Rosenthal, Sergey B. Mirov and Lacey R. McNally
Hadiyah-Nicole Green
1The University of Alabama at Birmingham, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William E. Grizzle
1The University of Alabama at Birmingham, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eben L. Rosenthal
1The University of Alabama at Birmingham, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergey B. Mirov
1The University of Alabama at Birmingham, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lacey R. McNally
1The University of Alabama at Birmingham, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2012-1972 Published April 2012
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL

Abstract

We combine active targeting, fluorescent imaging, and subsequent photothermal treatment of malignant cells as a viable approach for the treatment of a variety of cancer types that over-express the epidermal growth factor including head and neck, colorectal, ovarian, cervical, breast, bladder, pancreatic, and prostate cancers. In our photothermal therapy experiments, the use of a near infrared (NIR) laser enables us to take advantage of both the plasmon resonance absorption peak of gold nanorods (GNR), ∼785 nm with aspect ratio of ∼ 4, as well as the absorption peak of the fluorescent dye, ∼774 nm. We used a 785 nm NIR laser with fluence of ∼9.5 W/cm2 and a 4 minute exposure time. Anti- epidermal growth factor receptor (EGFR) antibody, which targets the epidermal growth factor receptor over-expressed on malignant head and neck cancer cells, was labeled with a fluorescent dye and conjugated to GNR. We have studied the conjugation parameters for GNR and anti-EGFR antibodies and used nearest neighbor approximations to analyze the nanorod-to-antibody ratio from transmission electron microscope images. The optimal conjugation of dye:antibody:GNR facilitates active targeting of the nanorods to the tumor site. This active targeting is more efficient than previously reported results that rely solely on the enhanced permeability and retention effect. We demonstrate that PEGylating the GNR before conjugation to antibodies improves the quality of the conjugation. We also show that binding ability of the conjugated antibody to the epidermal growth factor receptor has not been affected. In addition, cell death by NIR photothermal therapy and gold nanorods is not compromised following conjugation of gold nanorods to a fluorescently labeled antibody. NIR photothermal treatment with the dye-antibody-nanorod conjugate selectively heated the GNR, excited fluorescence, and was sufficient to kill nearly 90% of tumor cells comparable to photothermal therapy with the GNR alone.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1972. doi:1538-7445.AM2012-1972

  • ©2012 American Association for Cancer Research
Back to top
Cancer Research: 72 (8 Supplement)
April 2012
Volume 72, Issue 8 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 1972: Active targeting, fluorescence imaging, and NIR photothermal therapy of malignant tumors
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract 1972: Active targeting, fluorescence imaging, and NIR photothermal therapy of malignant tumors
Hadiyah-Nicole Green, William E. Grizzle, Eben L. Rosenthal, Sergey B. Mirov and Lacey R. McNally
Cancer Res April 15 2012 (72) (8 Supplement) 1972; DOI: 10.1158/1538-7445.AM2012-1972

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 1972: Active targeting, fluorescence imaging, and NIR photothermal therapy of malignant tumors
Hadiyah-Nicole Green, William E. Grizzle, Eben L. Rosenthal, Sergey B. Mirov and Lacey R. McNally
Cancer Res April 15 2012 (72) (8 Supplement) 1972; DOI: 10.1158/1538-7445.AM2012-1972
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Cancer Chemistry

  • Abstract 6550: WD105, a novel decursin derivative, showed greater growth inhibition and androgen receptor suppression in LNCaP human prostate cancer cells
  • Abstract 5696: Genetic reprogramming of TAMs by engineered exosomes results in potent single agent anti-tumor activity
  • Abstract 5709: Disruption of mitochondrial metabolism underlies the efficacy of devimistat in acute myeloid leukemia
Show more Cancer Chemistry

Poster Presentations - Proffered Abstracts

  • Abstract PO-048: MicroRNA-10b is a regulator of cellular viability and proliferation in fibrolamellar carcinoma
  • Abstract PO-055: Pan-cancer metabolic profiling of the tumor microenvironment
  • Abstract PO-041: Genome-wide CRISPR/Cas9 screen reveals mitochondrial gene mutation as a driver for drug resistance in Ewing sarcoma
Show more Poster Presentations - Proffered Abstracts

Poster Presentations - Nanoscale Drug Delivery Systems 1

  • Abstract 1968: Nanoparticle mediated measurement of target-drug binding in cancer cells
  • Abstract 1944: A novel vasoactive intestinal peptide-grafted curcumin nanomedicine for targeting breast cancer stem cells
Show more Poster Presentations - Nanoscale Drug Delivery Systems 1
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement